Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients

AIDS

Volumn 10, Issue 5, 1996, Pages

  Staszewski, Schlomo ^a   Miller, Veronica ^a   Rehmet, Sibylle ^a   Stark, Thomas ^a   De Crée, Jean ^b   De Brabander, Marc ^b   Peeters, Monika ^c   Andries, Koen ^c   Moeremans, Marc ^c   De Raeymaeker, Marc ^c   Pearce, Gillian ^d   Van Den Broeck, Remi ^d   Verbiest, Werner ^c   Stoffels, Paul ^c  

^a GOETHE UNIVERSITY   (Germany)

^b Research Unit   (Belgium)

^c JANSSEN RESEARCH FOUNDATION   (Belgium)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Antiviral therapy

Indexed keywords

ANTIGEN P24; ANTIVIRUS AGENT; CD4 ANTIGEN; LAMIVUDINE; LOVIRIDE; ZIDOVUDINE;

ABDOMINAL PAIN; ADULT; ANEMIA; ARTICLE; BACKACHE; BRONCHITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DIARRHEA; DRUG EFFICACY; DRUG RESISTANCE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; INSOMNIA; LEUKOPENIA; LYMPHOCYTE COUNT; MALE; MYCOSIS; NAUSEA; PHARYNGITIS; PRIORITY JOURNAL; PRURITUS; RASH; VIREMIA; VIROLOGY; VIRUS RESISTANCE; VISUAL DISORDER;

EID: 9244220064     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199605000-00001     Document Type: Article

References (17)

1. Pauwels R, Andries K, Debyser Z, et al.: Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of α-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proc Natl Acad Sci USA 1993, 90:1711-1715.
2. Coates JAV, Cammack N, Jenkinson HJ, et al.: (-)-2′-Deoxy-3′-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob Agent Chemother 1992, 36:672-676.
3. Staszewski S, Miller V, Kober A, et al.: Evaluation of the efficacy and tolerance of R018893, R089439 (loviride) and placebo in asymptomatic HIV-1 infected patients. Antiviral Ther 1996, 1:42-50.
4. Van Leeuwen R, Lange JMA, Hussey EK, et al.: The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a Phase I study. AIDS 1992, 6:1471-1475.
5. Van Leeuwen R, Katlama C, Kitchen V, et al.: Evaluation of safety and efficacy of 3TC in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study. J Infect Dis 1995, 171:1166-1171.
6. Eron JJ, Benoit SL, Jemsek J, et al.: Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med 1995, 333:1662-1669.
7. 3. Presented the International Congress on Drug Therapy in HIV Infection. Glasgow, November 1994.
8. Tisdale M, Kemp D, Parry N, Larder B: Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 1993, 90:5653-5656.
9. Boucher CAB, Cammack N, Schipper P, et al.: High-level resistance to (-)enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino-acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1993, 37:2231-2234.
10. Larder BA, Kemp SD, Harrigan PR: Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995, 269:696-699.
11. Larder BA, Kellam P, Kemp SD: Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro. Nature 1993, 365:451-453.
12. De Béthune MP, Pauwels R, Andries K, et al.: AZT resistance reversal by the non-nucleoside reverse transcriptase inhibitor α-APA R018893 in a symptomatic HIV-infected individual. II International Workshop on HIV Drug Resistance. Noordwijk, June 1993 [abstract 40].
13. Colebunders B, Staszewski S, Vandenbruaene M, et al.: The safety and pharmacokinetic results of loviride and of a combination of loviride and zidovudine therapy in HIV-infection. Presented at the International Conference on AIDS. Yokohama, August 1994.
14. Youle M, Davies S, Andries K, et al.: Randomized double-blind trial of loviride (R89439) (L), zidovudine (Z) and the combination in HIV-1 infected patients. 2nd National Conference on Human Retroviruses and Related Infections. Washington, DC, January-February 1995 [abstract LB6A].
15. Staszewski S, Massari FE, Kober A, et al.: Combination therapy with zidovudine prevents selection of human immunodefiency virus type 1 variants expressing high-level resistance to L-697,661, a nonnucleoside reverse transcriptase inhibitor. J Infect Dis 1995, 171:1159-1165.
16. Boom R, Sol CJA, Salimans MMM, Jansen CL, Wertheim-van Dillen, Van Der Noordaa J: Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990, 28:495-503.
17. Semple M, Loveday C, Weller I, Tedder R: Direct measurement of viraemia in patients infected with HIV-1 and its relationship to disease progression and zidovudine therapy. J Med Virol 1991, 35:38-45.